Genmab — Juli 2020

[Solsen]

Det var mest dette studie jeg tænker på https://www.clinicaltrials.gov/ct2/show/NCT04487080?recrs=ab&cond=Lung+Cancer&sfpd_s=07%2F16%2F2020&sfpd_d=14&sel_rss=new14 som der blev linket til i går.

[Helge_LarsenPI-redaktør]

God morgen.

[Plimsoller]

God morgen

[Mogan]

God morgen

[E_L]

British Journal of Haematology -
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16980

[E_L]

you can click on 'Read the full text' there . (doubt many will )

[E_L]

BioNTech announces another collaboration, with Regeneron for
Melanoma

[E_L]

New Topline TEPEZZA (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED) https://apnews.com/792e5d2d37194348be8940fa297fcd30

[Solsen]

HZNP, BNTX og HALO som alle er relateret til Genmab har givet super afkast til investorerne i år

[Helge_LarsenPI-redaktør]

En særmeddelelse: https://www.proinvestor.com/boards/85475

[AaBforever]

Tillykke Helge!!:-)

[GeorgeBest]

[E_L]

Well done Helge, congratulations

[E_L]

Seattle Genetics, Inc. (SGEN) CEO Clay Siegall on Q2 2020 Results - Earnings Call Transcript - on TV - https://seekingalpha.com/article/4362785-seattle-genetics-inc-sgen-ceo-clay-siegall-on-q2-2020-results-earnings-call-transcript?part=single

[Mcjean]

Tillykke godt gået, hvornår kan vi forvente IPO til en favorabel pris til de trofaste inden børsnoteringen?

[E_L]

[E_L]

MS $HZNP: Raising PT on higher Tepezza; Reiterate OW rating: Risinger is significantly boosting our Tepezza sales estimates, which drives our earnings and PT higher. He is raising our PT from $50 to $70, supported by new valuation methodology.

[E_L]

AbbVie- why the CD3xCD20 would be best in class - efficacy data reported puts it at higher end, safety profile has been very favourable , SC formulation, dosing schedule fits very well in the diseases we are looking at- that makes it a very strong profile

[Tommy_P.]

Tillykke Helge!!

[lom]

Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma